FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study
Executive Summary
FDA's internal disagreements about the value of GlaxoSmithKline's RECORD trial stem, in part, from different visions of the role agency reviewers should play in analyzing data